Bethesda, MD, USA (Nov. 1, 2012)—The technology used to develop a new vaccine as an aid in the prevention of clinical disease caused by Hendra virus in horses has been licensed from The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) by Pfizer Animal Health, a multinational animal health company with expertise in the discovery, development and manufacturing of innovative vaccines. The new vaccine, called Equivac® HeV, is now available for use in Australia. The vaccine's availability was announced today during a news conference held by Pfizer Animal Health in Brisbane, Australia.
The vaccine is derived from the original work of Christopher C. Broder, Ph.D., of the Uniformed Services University of the Health Sciences (USU) and Katharine Bossart, Ph.D., a USU alumna and assistant professor at Boston University School of Medicine. The National Institute of Allergy and Infectious Disease (NIAID), part of the U.S. National Institutes of Health, supported the work.
Progression of the technology is the result of a close, ongoing collaboration with Pfizer Animal Health and a team at Commonwealth Scientific and Industrial Research Organisation's (CSIRO) Australian Animal Health Laboratory (AAHL) in Geelong, Australia. The bio-security facility at AAHL is the only laboratory in the world where Hendra virus challenge testing of the vaccine in horses could have been accomplished, work presently under the direction of Deborah Middleton, D.V.P. Two years ago, Pfizer Animal Health joined this collaborative effort, bringing its development and regulatory expertise to facilitate the unprecedented rapid development, approval and deployment of this breakthrough vaccine.
Since its first appearance in 1994, the Hendra virus has killed more than 80 horses and four of the seven people infected to date. An equine vaccine is crucial to breaking the cycle of Hendra virus transmission from flying foxes to horses and then to people, as it helps prevent the horse from both developing the disease and transmitting the virus to other horses and to humans. Current experiments have shown that vaccinated horses survived infection by Hendra virus and have shown no evidence of virus, disease, replication or shedding of the virus, a critical finding to help prevent transmission.
"The vaccine component is a soluble portion of a Hendra virus G glycoprotein, known as Hendra-sG. It is this glycoprotein that mediates viral infection. If you block its function, you block virus infection," Broder said. Bossart developed Hendra-sG while a student in Broder's laboratory at USU. This is a type of vaccine known as a subunit, which is safe to use.
"We have shown that vaccination with test formulations containing Hendra-sG to be effective in helping to prevent Hendra infection. Studies with Hendra-sG glycoprotein have shown promise in helping to prevent infection by its close relative, Nipah virus," Broder said. The Hendra-sG glycoprotein results in horses confirm earlier experimental work by Broder and his colleagues, where formulation containing the protein was shown to be protective in other animal models of Hendra and Nipah virus infection, including ferret, feline and nonhuman primates. The viruses are found in several bat species in the Eastern hemisphere, but increasing evidence suggests they may be more widespread, stretching from Asia to West Africa.
Hendra virus has been found only in Australia. The nation experienced an unprecedented number of 18 outbreaks across Queensland and New South Wales in 2011, during which 22 horses died or were euthanized. Authorities detected the first case of Hendra virus antibodies in a dog within a natural environment that same year. The virus has appeared seven times in 2012, causing equine deaths and cases of human exposure to infection. In July 2012, a woman with significant exposure risk was given an experimental human monoclonal antibody therapy on a compassionate use basis. Dimitar Dimitrov, Ph.D., of the NIH, working in collaboration with Broder, developed the antibody, known as m102.4.
The Hendra and Nipah viruses, members of the paramyxovirus family, are highly infectious agents that emerged from flying foxes in the 1990s to cause serious disease outbreaks in humans and livestock in Australia, Bangladesh, India, Malaysia and Singapore. Recent Nipah outbreaks have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission, and greater than 75 percent case fatality rates among humans.
A collaborative group led by Broder has published its groundbreaking Hendra and Nipah virus work in two articles in Science Translational Medicine. A breakthrough in the development of an effective therapy against Hendra (and Nipah) virus that is now in development for use in people was published in an October 2011. The ability of a Hendra-sG based trial formulation to completely protect nonhuman primates from Nipah virus infection, that is paving the way for a potential human-use vaccine, was published in August 2011.
"We are pleased to have worked with The Henry M. Jackson Foundation, Uniformed Services University of the Health Sciences and CSIRO in the development of this innovative vaccine," said Catherine Knupp, Vice President, Veterinary Medicine Research and Development, Pfizer Animal Health. "Our involvement in the collaboration to develop Equivac HeV speaks to our determination to support the global veterinary community with effective vaccines to aid in the control of potentially life-threatening diseases such as the Hendra virus."
The recent work to develop and evaluate the Hendra vaccine Equivac® HeV was jointly funded by CSIRO; Pfizer Animal Health; the Australian government through its Department of Agriculture, Fisheries and Forestry; and the Queensland government through its Department of Employment, Economic Development and Innovation. NIAID provided funding to support production of the vaccine component in the U.S.
About HJF
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., (HJF) is a private, not-for-profit organization established in 1983 and authorized by the U.S. Congress to support medical research and education at the Uniformed Services University of the Health Sciences and throughout the military medical community. www.hjf.org.
About USU
The Uniformed Services University of the Health Sciences (USU) is the nation's federal health sciences university. USU students are primarily active duty uniformed officers in the Army, Navy, Air Force and Public Health Service who have received specialized education in tropical and infectious diseases, preventive medicine, the neurosciences, disaster response and humanitarian assistance, and acute trauma care. A large percentage of the university's more than 4,800 physician and 600 advanced practice nursing alumni are supporting operations around the world, offering their leadership and expertise. USU's graduate programs in biomedical sciences and public health, committed to excellence in research, have awarded approximately 400 doctoral and more than 900 masters degrees to date. www.usuhs.mil.
About CSIRO
CSIRO, the Commonwealth Scientific and Industrial Research Organisation, is Australia's national science agency and one of the largest and most diverse research agencies in the world. www.csiro.au.
About Pfizer Animal Health
Pfizer Animal Health is committed to the health and wellbeing of animals, through providing reliable and effective medications for companion animals. We take pride in being leaders in animal healthcare and providing innovative solutions to challenging health issues. We have a leading portfolio of medicines that prevent, treat and cure diseases across a broad range of therapeutic areas, and an industry-leading pipeline of promising new products in current and future areas of medicine. Pfizer has Australian-based research and manufacturing facilities as well as major locations in the US, Asia and Europe so we can deliver quality products with a focus on Australian needs. Pfizer Australia is the largest animal health company in Australia, with a base in Sydney and a large team of field based representatives and veterinarians.
® registered trademark of Pfizer Animal Health